Bhavesh Mohan Lal

M.D.

UAMS

Also affiliated: University of Arkansas Medical Center (2025); All India Institute of Medical Sciences (2021–2026)

6 h-index 39 pubs 127 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Bhavesh Mohan Lal's research focuses on hematologic malignancies, particularly multiple myeloma, and the application of advanced therapies such as CAR-T cell therapy and bispecific antibodies. He has investigated the influence of prior treatments, like belantamab mafodotin, on outcomes with subsequent therapies in multiple myeloma patients. Lal has also contributed to systematic reviews examining the safety and efficacy of CAR-T cell therapy in autoimmune diseases and the association between autoimmune encephalitis and COVID-19 or its vaccines. His work extends to exploring myelodysplastic syndromes, including their pathogenic mechanisms and therapeutic advancements. Additionally, Lal has studied the use of ultrasonography for obstructive sleep apnea diagnosis and investigated pneumothorax and pneumomediastinum in COVID-19 patients.

Metrics

h-index: 6
Publications: 39
Citations: 127

Positions

M.D. publications 2024–2026

University of Arkansas for Medical Sciences Institution web page

Selected Publications

Association Between Metabolic Syndrome and Prostate Cancer: A Systematic Review (2026)

Cancers DOI OpenAlex
Social vulnerability index as an independent poor prognostic factor in patients with chronic hematological malignancies in Arkansas. (2026)

Journal of Clinical Oncology DOI OpenAlex
New Approaches for Measurable Residual Disease Assessment in Multiple Myeloma: Integrating NGS, Mass Spectrometry, and Next-Generation Flow Cytometry to Monitor Treatment Response (2026)

Current Hematologic Malignancy Reports DOI OpenAlex
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)

Blood Cancer Journal 2 citations DOI OpenAlex
Critical platelet shortages and a single Institution's experience with split platelet transfusions: Can you get by with just half a unit? (2025)

Blood DOI OpenAlex
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2025)

Blood Cancer Journal 19 citations DOI OpenAlex
Incidentally Detected Pulmonary Carcinoid Tumorlet With Coexisting Carcinoid Tumorlet in the Mediastinal Lymph Node in a Patient With Lung Cancer (2025)

Case Reports in Pulmonology DOI OpenAlex
International Medical Graduates Representation at International Oncology Conference Meetings: An Analysis of ASCO Annual Meetings (2025)

JCO Oncology Practice 2 citations DOI OpenAlex
Prognostic significance of neutrophil-to-lymphocyte ratio in small cell lung cancer in the era of immunotherapy. (2025)

Journal of Clinical Oncology DOI OpenAlex
Impact of demographic and socioeconomic factors on survival outcomes in patients with Waldenstrom macroglobulinemia: A SEER database analysis from 2000-2021. (2025)

Journal of Clinical Oncology DOI OpenAlex
Epidemiological and clinical trends in common hematological malignancies in Arkansas: Arkansas Central Cancer Registry (ACCR)-based study. (2025)

Journal of Clinical Oncology DOI OpenAlex
Incidence and impact of incidental pulmonary embolism in solid cancer patients. (2025)

Journal of Clinical Oncology DOI OpenAlex
MRI lesion burden as a predictor of progression and survival in smoldering multiple myeloma. (2025)

Journal of Clinical Oncology DOI OpenAlex
NSCLC in the immunotherapy era: Trends in survival and disparities across demographic and socioeconomic groups. (2025)

Journal of Clinical Oncology 2 citations DOI OpenAlex
Patterns of mortality in lung cancer patients in the era of immunotherapy and targeted therapy: A single-center, retrospective, observational study. (2025)

Journal of Clinical Oncology DOI OpenAlex